Zobrazeno 1 - 10
of 221
pro vyhledávání: ''
Autor:
Hélène Labussière-Wallet, Stephanie Nguyen-Quoc, Amandine Luc, Thomas Remen, Jacques-Olivier Bay, Edouard Forcade, Rémi Dulery, Marie-Thérèse Rubio, Célestine Simand, Micha Srour, Maud d'Aveni, Ambroise Marçais, Sabine Furst, Arnaud Campidelli, Patrice Ceballos, Etienne Daguindau, Marie Robin, Pascal Turlure
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
Clinical Lymphoma, Myeloma & Leukemia, Elsevier, In press, ⟨10.1016/j.clml.2021.07.027⟩
International audience; BackgroundAllogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome . We retrospectively compared patient outcomes after allo-HSCT according to the i
Autor:
Daniel A. Pollyea, Anagha Inguva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:805-811
The use of venetoclax in combination with hypomethylating agents (HMA) has changed the paradigm for the treatment of acute myeloid leukemia (AML) in elderly patients and those unfit for intensive chemotherapy. A phase 3 study has shown superior respo
Autor:
Courtney Nicole Miller-Chism, Harinder S. Juneja, Curtis Lachowiez, Hilary Y. Ma, Martha P. Mims, Wei Qiao, Onyebuchi Ononogbu, Mark M. Udden, Effrosyni Apostolidou
Publikováno v:
Clin Lymphoma Myeloma Leuk
Despite therapeutic advances and improvement in outcomes of patients with acute lymphoblastic leukemia, as reported by specialized centers, healthcare disparities exist. This is a retrospective cohort analysis of the clinical outcomes of 146 patients
Autor:
Philomena Colucci, Jingbo Yu, Jonathan Kish, Dilan Paranagama, Shreekant Parasuraman, Kevin C Lord, Ivy Altomare
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e915-e921
Background Polycythemia vera (PV) is a myeloproliferative neoplasm affecting >100,000 people in the United States annually. Patients (pts) with PV are at risk for thromboembolic events (TEs), premature death, and high symptom burden. Hydroxyurea (HU)
Autor:
Jean El Cheikh, Iman Abou Dalle, Jeries Kort, Farouk Al Chami, Maya Charafeddine, Haidar El Darsa, Rola El Sayed, Ali Ibrahim, Ali Bazarbachi
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:711-719
Background Intensified immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP) improves outcomes in younger adults with diffuse large B-cell lymphomas (DLBCL) compared with R-CHOP. Due to vinde
Autor:
William R. Drobyski, Nirav N. Shah, Walter L. Longo, Timothy S. Fenske, Bicky Thapa, Anita D'Souza, Sergey Tarima, Muhammad Bilal Abid, Saurabh Chhabra, Huaying Dong, Parameswaran Hari, Binod Dhakal, Mehdi Hamadani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e775-e781
Engraftment syndrome (ES) after autologous hematopoietic cell transplantation (AHCT) in multiple myeloma (MM) encompasses a continuum of periengraftment complications characterized by noninfectious fever, rash, diarrhea, and capillary leak features.W
Autor:
Tara Cronin, Kristopher Attwood, Eunice S. Wang, Sarah Sadek, Mark G. Faber, Swapna Thota, James E. Thompson, Jeffrey Baron, Ellen Madarang, Elizabeth A. Griffiths, Justin M. Watts, Terrence Bradley, Amanda Przespolewski, Abhay Singh
Publikováno v:
Clin Lymphoma Myeloma Leuk
The optimal approach to combine gemtuzumab-ozogamicin (GO) with various chemotherapy backbones and other newer agents safely remains to be determined. We performed a retrospective analysis of the safety and outcomes of newly diagnosed adult AML patie
Autor:
Rasmus T. Hoeg, Matthew E. Tenold, Rajeev Krishnan, Mehrdad Abedi, Brian A. Jonas, Aaron S. Rosenberg, Joseph Tuscano, Benjamin N Moskoff
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e611-e618
Background FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically
Autor:
Theodore Argyrakos, Dimitrios Galopoulos, John V. Asimakopoulos, Panagiotis Toulas, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos, Kostas Konstantopoulos, Stavrianna Diavati, Iliana Konstantinou
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e601-e605
Clinical Practice Points • Progressive multifocal leukoencephalopathy (PML) is a rare but fatal demyelinating disease caused by John Cunningham polyomavirus, mainly affecting immunosuppressed patients. It sporadically complicates hematological mali
Autor:
Onder Alpdogan, Vinicius Jorge, Andrew Tiu, Claudia Dourado, Djeneba Audrey Djibo, Sorab Gupta, Peter Moussa
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:205-215
Diffuse large B-cell lymphoma (DLBCL) comprises approximately 30% of all non-Hodgkin lymphomas. Multiple studies have demonstrated race-based disparities in survival among patients with DLBCL across all stages of disease, in the era both before and a